Our Services
Clinical Trial Management Services
Central Laboratory Services
Clinical Pharmacology
Scintigraphy
Pharmacovigilance
Regulatory Affairs
Clinical & Medical Writing
Clinical Trial Management Services
Phase I
Phase II
Phase III
Site Management & Monitoring
IMP Management
Biometric Services
Several inflammatory cytokines that promote inflammation and pathogenesis in asthma signal through the Janus kinase 1 (JAK1) pathway. This phase I, randomized, placebo-controlled trial assessed the pharmacokinetics and safety of single and multiple ascending doses up to 15 mg twice daily for 14 days of a JAK1 inhibitor, GDC-0214, in healthy volunteers (HVs; n = 66).
